Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0000950170-25-038216

Chief Executive Officer sold 14,435 shares at an average $42.70 ($616,349)

  • Chief Executive Officer acquired 28,250 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Kulkarni Samarth · Chief Executive Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2025-03-10 Exercise or conversion : show line 1 in the form +19,250 190,863 D
2025-03-11 Sale : show line 2 in the form −9,973 $42.42 $423,055 180,890 D
2025-03-11 Exercise or conversion : show line 3 in the form +9,000 189,890 D
2025-03-12 Sale : show line 4 in the form −4,462 $43.32 $193,294 185,428 D
Open-market sales · 14,435 sh · avg $42.70 · $616,349

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2025-03-10 Exercise or conversion : show line 5 in the form Restricted Stock Units −19,250 38,500 D
2025-03-11 Exercise or conversion : show line 6 in the form Restricted Stock Units −9,000 0 D
Loading xslF345X05/ownership.xml…